This study is designed to evaluate the efficacy and safety of guide-free sacroiliac joint (SIJ) injection in refractory sacroiliac pain due to spondyloarthropathies.
A 20 weeks open-label clinical trial study of 35 patients, with different subtypes of spondyloarthropathies, is conducted In spondyloarthropathy's patients with refractory inflammatory buttock pain (fulfilling inclusion criteria), we performed outpatient guide-free sacroiliac injection of triamcinolone acetonide 40 mg in each joint. Patient (pain, stiffness, sleep disturbance) and Clinician assessments (sacroiliac tenderness, Finger to floor and Schober tests ) are recorded at baseline and every 4 weeks until the end of the study. MRI scoring of sacroiliac joint is recorded according to the Spondyloarthritis Research Consortium of Canada (SPARCC) magnetic resonance imaging (MRI) index for scoring inflammatory lesions in the sacroiliac joints, at baseline and in the end of the study.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
35
guide-free sacroiliac injection of triamcinolone acetonide 40 mg in each sacroiliac joint
Tabriz Medical University, Rheumatology Department
Tabriz, East Azarbayjan, Iran
Refractory inflammatory sacroiliac pain
Time frame: 8 months
ESR, CRP
Time frame: 8 months
Patient's assessment of: pain, sleep disturbance, morning stiffness
Time frame: 8 months
Clinician assessment of: SIJ pain, change of finger to floor (cm) and Schober tests (mm)
Time frame: 8 months
MRI SIJ inflammatory scoring
Time frame: 8 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.